Medpace Holdings (MEDP) risk factors, FY2025 10-K

Business and Economic Risks

1. 01The potential loss, delay or non-renewal of our contracts, or the non-payment by our customers for services that we have performed, could adversely affect our results
2. 02We experience termination, cancellation and non-renewals of contracts by our customers in the ordinary course of business, and the number and dollar value of cancellations can vary significantly from year to year
3. 03Our backlog may not convert to net revenue at our historical conversion rates
4. 04delivery against project schedules, scope changes, contract terminations and the nature, duration and complexity of the contracts, and can vary significantly over time
5. 05Our operating results have historically fluctuated between fiscal quarters and years and may continue to fluctuate in the future, which may adversely affect the market price of our stock
6. 06Our operating margins could decrease due to increased pricing pressure or other pressures, if we are unable to either achieve efficiencies in our operating expenses or grow revenues at a rate faster than expenses
7. 07Our customer or therapeutic area concentration may have a material adverse effect on our business, financial condition, results of operations or cash flows
8. 08We bear financial risk if we underprice our fixed-fee contracts or overrun cost estimates, and our financial results can also be adversely affected by failure to receive approval for change orders or delays in documenting change orders
9. 09Our business and operations may be impacted in the future by epidemics, pandemics or widespread public health crisis
10. 10If we are unable to successfully execute our growth strategies or manage our growth effectively, our results of operations or financial condition could be adversely affected
11. 11If we are unable to recruit suitable investigators and enroll patients for our customers’ clinical trials, our clinical development business may suffer
12. 12The failure of third parties to provide us critical support services could materially adversely affect our business, financial condition, results of operations, cash flows or reputation
13. 13Current or potential future investments by the Company in our customers’ businesses or products could have a negative impact on our financial results
14. 14Our business depends on the continued effectiveness and availability of our information systems, including the information systems we use to provide our services to our customers, such as ClinTrak, and failures of these systems may materially limit our operations
15. 15If the security of confidential information used in connection with our services is breached or otherwise subject to unauthorized access, our reputation and business may be materially harmed

International Risks

1. 16Our business is subject to international economic, political and other risks that could negatively affect our results of operations and financial condition
2. 17Due to the global nature of our business, we may be exposed to liabilities under the Foreign Corrupt Practices Act and various other anti-corruption laws, and any allegation or determination that we violated these laws could have a material adverse effect on our business

Industry Risks

1. 18Outsourcing trends in the biopharmaceutical industry and changes in aggregate expenditures and R&D budgets could adversely affect our operating results and growth rate
2. 19We may be affected by healthcare reform and potential additional regulatory reforms, which may adversely impact the biopharmaceutical industry or otherwise reduce the need for our services or negatively impact our profitability
3. 20Consolidation in the biopharmaceutical industry could lead to a reduction in our revenues
4. 21The biopharmaceutical industry has a history of patent and other intellectual property litigation, and we might be involved in costly intellectual property lawsuits
5. 22If we do not keep pace with rapid technological changes, including AI, our services may become less competitive or obsolete
6. 23Circumstances beyond our control could cause the CRO industry to suffer reputational or other harm that could result in an industry-wide reduction in demand for CRO services, which could harm our business

Other Legal, Regulatory, Insurance and Tax Risks

1. 24If we fail to perform our services in accordance with contractual requirements, government regulations and ethical considerations, we could be subject to significant costs or liability and our reputation could be adversely affected28% rewritten
2. 25fines or penalties. In addition, negative publicity regarding regulatory compliance of our customers’ clinical trials, programs or products could have an adverse effect on our business and reputationNew
3. 26Some of our services involve direct interaction with clinical trial patients and operation of a Phase I clinical facility, which could create potential liability that may adversely affect our results of operations and financial condition
4. 27Our clinical development services could subject us to potential liability that may adversely affect our results of operations and financial condition
5. 28Our operations involve the use and disposal of hazardous substances and waste which can give rise to liability that could adversely impact our financial condition
6. 29We act as legal representative and/or data representative for some clients
7. 30Our insurance may not cover all of our indemnification obligations and other liabilities associated with our operations
8. 31Our effective income tax rate may fluctuate, which may adversely affect our operations, earnings and earnings per share
9. 32If we fail to comply with federal, state and foreign healthcare laws, including fraud and abuse laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected
10. 33Laws and regulations regarding the protection of personal data could result in increased risks of liability or increased cost to us or could limit our service offerings
11. 34Environmental, Social and Governance initiatives could increase our costs, and inaction could harm our reputation and adversely impact our financial results
12. 35Our Chief Executive Officer and founder controls a substantial amount of our outstanding common stock and his interests may be different from or conflict with those of our other shareholders24% rewritten
13. 36We are party to transactions with related persons that may increase the risk of allegations of conflicts of interest, and such allegations may impair our ability to realize the benefits we expect from these transactions

General Risks

1. 37If we lose the services of key personnel or are unable to recruit experienced personnel, our business could be adversely affected
2. 38Our operations might be affected by the occurrence of a natural disaster or other catastrophic event